Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts

TAS-102 is a novel oral nucleoside antitumor agent that consists of trifluridine (FTD) and tipiracil hydrochloride (TPI) at a molecular ratio of 1:0.5, and was approved in Japan in March 2014 for the treatment of patients with unresectable advanced or recurrent colorectal cancer that is refractory t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Rep
Autors principals: TSUKIHARA, HIROSHI, NAKAGAWA, FUMIO, SAKAMOTO, KAZUKI, ISHIDA, KEIJI, TANAKA, NOZOMU, OKABE, HIROYUKI, UCHIDA, JUNJI, MATSUO, KENICHI, TAKECHI, TEIJI
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2015
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4391594/
https://ncbi.nlm.nih.gov/pubmed/25812794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2015.3876
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars